Skip to main content

Catalyst Calendar

Scope

Thu, Aug 13, 2026

1 updates
MDWD
7:00 AM

MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update

EscharEx ® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid ® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26

Enrollment • Phase 3Enrollment completion Wed, Mar 31, 2027mediwound.com

Wed, Jul 29, 2026

1 updates
MDWD
8:00 AM

MediWound to Report Second Quarter 2026 Financial Results

MediWound to Report Second Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, August 13 at 8:30 a.m. Eastern Time YAVNE, Israel, July 29, 2026 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today

mediwound.com

Wed, May 27, 2026

1 updates
MDWD
7:00 AM

MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update

EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed at $24-26 million Conference Call Today, May 27, 2026, at 8:30 a.m.

Enrollment • Phase 3Enrollment completion Wed, Mar 31, 2027, 8:30 AM ETmediwound.com